证券之星消息，11月25日生物制品板块较上一交易日上涨0.83%，金迪克领涨。当日上证指数报收于 3870.02，上涨0.87%。深证成指报收于12777.31，上涨1.53%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000403 | 派林生物 | 15.12 | -1.69% | 13.03万 | 1.98亿 | | 688331 | 荣昌生物 | 87.50 | -0.97% | 5.53万 | 4.93 Z | | 688278 | 特宝生物 | 77.83 | -0.83% | 1.29万 | 1.01亿 | | 301080 | 百普赛斯 | 57.77 | -0.77% | 9883.3 | 5749.98万 | | 920047 | 诺思兰德 | 24.92 | -0.56% | 2.97万 | 7455.24万 | | 000534 | 万泽股份 | 20.74 | -0.43% | 15.50万 | 3.24亿 | | 688443 | 智 ...

【#带状疱疹及九价HPV疫苗促销席卷多地# 多家企业参与】九价HPV与带状疱疹疫苗在国内多个省市 地区已开展促销，让利幅度从最低3折到"打一送一"不等，参与企业包括智飞生物、百克生物等。有参 与促销的企业表示，"这是惠民降价，主要为配合加强公众疾病预防意识等。"但也有业内人士告诉智通 财经记者，当前一些头部疫苗企业存货数量较多，因为存在有效期，促销是减少库存的最佳手段。（智 通财经） ...

Core Insights - The promotion of nine-valent HPV and shingles vaccines has been initiated in various provinces and cities in China, with discounts ranging from 30% to "buy one get one free" [1] - Participating companies include Zhifei Biological and Baike Biological, indicating a competitive market environment [1] - The promotions are aimed at enhancing public awareness of disease prevention, although some industry insiders suggest that high inventory levels among leading vaccine companies are driving these promotional efforts [1] Company Insights - Zhifei Biological and Baike Biological are actively participating in the promotional campaigns, reflecting their strategies to boost sales and market presence [1] - The promotional activities may indicate a shift in pricing strategies within the vaccine sector, as companies seek to attract more consumers [1] Industry Insights - The current promotional efforts highlight a trend in the vaccine industry towards price reductions and increased accessibility for consumers [1] - The presence of significant inventory among leading vaccine manufacturers suggests potential challenges in inventory management and product expiration [1]

HPV疫苗价格降至一杯奶茶钱，流感疫苗甚至跌至个位数……在疫苗行业愈发"内卷"的当下，中国疫苗 行业协会发声，倡议协会会员坚决抵制无序低价竞争，严禁以低于成本的报价参与竞标。目前，中国疫 苗行业协会会员达到334家，主要疫苗厂商均涵盖在内。 疫苗行业的价格战，也使相关企业业绩出现承压，今年前三季度，A股14家疫苗企业中，有10家企业归 属净利润同比出现下滑，其中万泰生物、百克生物、智飞生物等更是由盈转亏。在业内人士看来，上述 倡议若能有效落实，有助于遏制恶性价格战，稳定市场价格环境，从而减少企业利润压力，促进资源向 研发和创新倾斜。 严禁以低于成本报价参与竞标 11月19日，中国疫苗行业协会发布《关于反对"内卷式"竞争 促进疫苗及其相关生物制品行业高质量发 展的倡议》。中国疫苗行业协会表示，该倡议旨在通过强化自律、鼓励创新，助力行业打破"内卷"，构 建健康有序的良性生态，共同开启以质量、安全、创新为核心的行业发展新篇章。 倡议提到，中国疫苗行业协会全体会员须严格遵循《中华人民共和国疫苗管理法》《中华人民共和国价 格法》，严格遵守行业自律公约，坚持公平、合法、诚实信用原则，以生产经营成本与市场供求状况为 定价基 ...

Core Viewpoint - The Chinese Vaccine Industry Association has issued an initiative to combat "involution" competition in the vaccine sector, aiming to promote high-quality development and establish a healthy competitive environment in the industry [1][2]. Group 1: Initiative Details - The initiative mandates all members of the Chinese Vaccine Industry Association to adhere to the Vaccine Administration Law and the Price Law of the People's Republic of China, ensuring fair and legal pricing based on production costs and market demand [1]. - Members are required to resist disorderly low-price competition and are prohibited from participating in bidding with prices below cost, thereby ensuring product and service quality standards [1][2]. Group 2: Industry Context - The association currently has over 330 member units and 35 branches, encompassing major vaccine and biological product companies, as well as upstream and downstream service providers in the biopharmaceutical industry [4]. - A price war has emerged in the public market, with significant price drops observed. For instance, the bid price for a trivalent flu vaccine from Shanghai Biological Products Research Institute was set at 5.5 yuan per dose in September, marking a new low in the public flu vaccine market [4]. - The price of a bivalent HPV vaccine from Watson Bio was reduced to 27.5 yuan per dose in a procurement project, humorously compared to the cost of a cup of milk tea [4]. Group 3: Financial Impact - The price war reflects a phenomenon of homogenized competition within the industry, leading to financial pressure on vaccine companies. In the first three quarters of this year, 10 out of 14 listed vaccine companies reported a year-on-year decline in net profit [5]. - Notably, five companies, including Zhifei Biological Products and Kanglaite, reported significant losses, totaling over 12 billion yuan for Zhifei alone [5]. - Industry insiders have expressed concerns that some companies are engaging in price wars to survive or capture market share, hoping for further national measures to address the issue of "involution" [5].

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

截至9月30日，百克生物股东户数1.08万，较上期增加7.23%；人均流通股38216股，较上期减少6.74%。 2025年1月-9月，百克生物实现营业收入4.74亿元，同比减少53.76%；归母净利润-1.58亿元，同比减少 164.76%。 分红方面，百克生物A股上市后累计派现2.35亿元。近三年，累计派现1.94亿元。 11月14日，百克生物涨1.93%，成交额2.35亿元。两融数据显示，当日百克生物获融资买入额4197.35万 元，融资偿还3150.43万元，融资净买入1046.92万元。截至11月14日，百克生物融资融券余额合计2.37 亿元。 融资方面，百克生物当日融资买入4197.35万元。当前融资余额2.36亿元，占流通市值的2.40%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，百克生物11月14日融券偿还6500.00股，融券卖出1800.00股，按当日收盘价计算，卖出金额 4.28万元；融券余量2.70万股，融券余额64.20万元，低于近一年30%分位水平，处于低位。 资料显示，长春百克生物科技股份公司位于吉林省长春市朝阳区卓越大街138号，成立日期2004年3月4 日， ...

Core Viewpoint - The company has no plans for acquisition and is focused on its long-term development while enhancing its core competitiveness in the vaccine sector [2] Group 1: Company Strategy - The company emphasizes high-quality development and is actively advancing its research, production, and sales efforts [2] - The company is committed to improving its product pipeline, particularly in adult vaccines, multi-valent vaccines, and mRNA vaccines [2] Group 2: Market Environment - The company acknowledges the opportunities and challenges presented by an aging population and the emergence of new technologies and products [2] - The company aims to enhance its investment value and shareholder return capabilities based on quality improvement [2]

证券代码：688276 证券简称：百克生物 公告编号：2025-044 长春百克生物科技股份公司 关于选举第六届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司章程指引 （2025 年修订）》等法律法规、规范性文件及《长春百克生物科技股份公司章 程》（以下简称"《公司章程》"）《长春百克生物科技股份公司董事会议事规 则》的相关规定，长春百克生物科技股份公司（以下简称"公司"）董事会设职 工代表董事一名。公司于 2025 年 11 月 14 日召开职工代表大会，会议的召开及 表决程序符合职工代表大会决策的有关规定，经民主讨论、表决，全体职工代表 一致审议通过了《关于选举第六届董事会职工代表董事的议案》，同意选举佟雪 莲女士（简历详见附件）为公司第六届董事会职工代表董事，任期自本次职工代 表大会审议通过之日起至公司第六届董事会任期届满之日止。 佟雪莲女士符合《公司法》《公 ...

（文章来源：证券日报） 证券日报网讯 11月14日晚间，百克生物发布公告称，公司于2025年11月14日召开职工代表大会审议通 过了《关于选举第六届董事会职工代表董事的议案》，同意选举佟雪莲女士为公司第六届董事会职工代 表董事，任期自本次职工代表大会审议通过之日起至公司第六届董事会任期届满之日止。 ...